OTHER (INCOME) EXPENSE , NET - Narrative (Details) - USD ($) $ in Millions					12 Months Ended
	Sep. 28, 2018	Mar. 01, 2018	Dec. 28, 2017	Jun. 30, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Schedule Of Other Income And Expenses [Line Items]
Favorable (unfavorable) adjustment, litigation and other matters					$ 27	$ (226)	$ (59)
Salix
Schedule Of Other Income And Expenses [Line Items]
Favorable (unfavorable) adjustment, litigation and other matters							(90)
Salix | Xifaxan®, Relistor® and Apriso®
Schedule Of Other Income And Expenses [Line Items]
Favorable (unfavorable) adjustment, litigation and other matters							$ 39
Salix Ltd. SEC Investigation Litigation
Schedule Of Other Income And Expenses [Line Items]
Favorable (unfavorable) adjustment, litigation and other matters	$ 40				$ 40
Allergan Shareholder Class Actions
Schedule Of Other Income And Expenses [Line Items]
Litigation settlements			$ 290
Allergan Shareholder Class Actions | Valeant Co Parties
Schedule Of Other Income And Expenses [Line Items]
Litigation settlements						96
Solodyn Antitrust Class Actions
Schedule Of Other Income And Expenses [Line Items]
Litigation settlements						93
Mimetogen Pharmaceuticals Litigation
Schedule Of Other Income And Expenses [Line Items]
Litigation settlements		$ 26		$ 20		$ 20